ReviewFrontiers in immunology2026
The oral-lung axis in lung cancer: microbial translocation, immune reprogramming, and clinical implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The oral-lung axis describes microbial and inflammatory exchange between the oral cavity and the lower respiratory tract. Its relevance to lung cancer is supported by the detection of oral-associated taxa in lower-airway samples, epidemiological links between periodontal disease and lung cancer risk, and experimental evidence that microbial signals can modify epithelial proliferation and antitumor immunity. This review integrates epidemiological, ecological, mechanistic, and translational evidence while distinguishing oral-associated or source-linked observations from pulmonary and intratumoral mechanisms in which oral origin has not been demonstrated. Particular attention is given to repeated microaspiration, Th17/IL-17 inflammation, NOD2/NF-κB and PI3K/ERK signaling, microbial metabolites, and remodeling of the tumor immune microenvironment. Recent studies of pulmonary nodules, radiotherapy, and immune checkpoint inhibition extend this field from disease association to clinically testable questions. The available evidence is most consistent with context-dependent tumor promotion and treatment-response modulation, rather than independent microbial initiation of human lung cancer. We conclude by defining the source-tracking, analytical, prospective, and interventional studies needed to establish causality and clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.